Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, Badoual C, Tedgui A, Fridman WH, Oudard S. Tartour E, et al. Among authors: karadimou a. Cancer Metastasis Rev. 2011 Mar;30(1):83-95. doi: 10.1007/s10555-011-9281-4. Cancer Metastasis Rev. 2011. PMID: 21249423 Review.
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J. Beuselinck B, et al. Among authors: karadimou a. Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12. Clin Cancer Res. 2015. PMID: 25583177 Free article.
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548. Br J Cancer. 2013. PMID: 23462807 Free PMC article.
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Beuselinck B, et al. Among authors: karadimou a. BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15. BJU Int. 2014. PMID: 24215209
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20. Acta Oncol. 2014. PMID: 23421954
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Acta Oncol. 2014 Oct;53(10):1413-22. doi: 10.3109/0284186X.2014.918276. Epub 2014 May 30. Acta Oncol. 2014. PMID: 24874929
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P. Beuselinck B, et al. Among authors: karadimou a. Br J Cancer. 2012 Nov 6;107(10):1665-71. doi: 10.1038/bjc.2012.385. Br J Cancer. 2012. PMID: 23132391 Free PMC article.
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Bamias A, et al. Among authors: karadimou a. BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45. BMC Cancer. 2010. PMID: 20163744 Free PMC article.
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.
Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, Karadimou A, Lainakis GA, Papadoukakis S, Stravodimos K, Dimopoulos MA, Patsouris E, Gakiopoulou H, Korkolopoulou P. Stofas A, et al. Among authors: karadimou a. BMC Cancer. 2014 Mar 4;14:149. doi: 10.1186/1471-2407-14-149. BMC Cancer. 2014. PMID: 24593195 Free PMC article.
25 results